Speech-Language Pathologists in Moncks Corner, SC Accepting Medicare

10 Speech-Language Pathologists found. Showing 1 - 10

Mrs. Kelly Murchison Brown, MSP,CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1060 Sugar Hill Dr, Moncks Corner, SC 29461 Phone: 843-899-7898

Berkeley County School District Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 229 E Main St, Moncks Corner, SC 29461 Phone: 843-899-8600

Berkeley County School District Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 406 W Main St, Moncks Corner, SC 29461 Phone: 843-899-8800    Fax: 843-899-8810

Ashley Elizabeth Manilenko, M.A., CCC-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 505 S Live Oak Dr, Moncks Corner, SC 29461 Phone: 843-761-8368

Miss Lindsey Jeanne Woodruff, M.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 777 Stony Landing Rd, Moncks Corner, SC 29461 Phone: 843-899-8870

Elan Hutchinson, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 320 N Live Oak Dr, Moncks Corner, SC 29461 Phone: 184-389-9880

Emily Estes Puckett, M.S. CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 421 Barony St Ste 3, Moncks Corner, SC 29461 Phone: 843-790-4093

Sarah Elizabeth Kirby, MCD CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 421 Barony St Ste 3, Moncks Corner, SC 29461 Phone: 843-790-4093    Fax: 843-501-2297

Ashlyn Farwell, M.S., CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 421 Barony St Ste 3, Moncks Corner, SC 29461 Phone: 843-790-4093    Fax: 843-501-2297

Kay Ford Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 109 E Main St, Moncks Corner, SC 29461 Phone: 843-899-8890

News Archive

Study examines the incidence and risk factors associated with Hepatitis C infection in rural Egypt

The prevalence of antibodies to Hepatitis C Virus (HCV) in Egypt is among the highest in the world. From the 1950s until 1982 hundreds of thousands were infected during mass campaigns to control schistosomiasis (a parasitic disease) using mass therapy with intravenous antimony compounds, but little is known about current risk factors and rates of transmission.

Hyperion HPN-100 phase III pivotal study for urea cycle disorders meets primary endpoint

Hyperion Therapeutics, Inc. today announced that the Company's phase III pivotal study of glycerol phenylbutyrate (HPN-100), an investigational drug for the treatment of urea cycle disorders (UCDs), met its primary endpoint. The non-inferiority study, conducted under a Special Protocol Assessment (SPA) granted by the U.S. Food and Drug Administration (FDA) in June 2009, evaluated the ammonia control of glycerol phenylbutyrate as compared to sodium phenylbutyrate (BUPHENYL®).

Temple researchers receive $1.25M NIH grant to advance understanding of neurodegenerative diseases

Like wear and tear that causes electrical systems to short circuit, neurons in the human nervous system are susceptible to degenerative processes that disrupt the flow of information.

NASDAQ Stock Market issues deficiency letter to NUCRYST Pharmaceuticals

NUCRYST Pharmaceuticals, a developer and manufacturer of medical products that fight infection and inflammation, today announced that on September 15, 2009 it received notice from the Nasdaq Stock Market that it no longer complies with Nasdaq Marketplace Rule 5550(a)(2) because, for the previous 30 consecutive business days, the bid price of its common stock had closed below the minimum requirement of $1.00 per share.

Cannabis Science enters into long-term lease on 9,500 square foot facility in Denver, Colorado

Cannabis Science, Inc., a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to announce that it has entered into a long-term lease on a 9,500 square foot facility in Denver, Colorado, that will become its corporate offices, as well as serving as a research facility for developing, testing, and producing medical cannabis for patients in compliance with the new Colorado laws regulating medical marijuana in the state.

Read more Medical News

› Verified 5 days ago